Biomarker guided therapy for heart failure: focus on natriuretic peptides

[1]  Pedro Lozano.  Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.

[2]  M. Gheorghiade,et al.  Acute heart failure syndromes , 2009, Journal of the American College of Cardiology.

[3]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[4]  I. Piña,et al.  BNP-guided therapy for heart failure. , 2009, JAMA.

[5]  K. Schulman,et al.  Early and long-term outcomes of heart failure in elderly persons, 2001-2005. , 2008, Archives of internal medicine.

[6]  M. Gheorghiade,et al.  EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan , 2008, Expert review of cardiovascular therapy.

[7]  O. Nielsen,et al.  Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics -- a randomized Danish multicenter study. , 2008, American heart journal.

[8]  P. Saiviroonporn,et al.  Correlation Between NT-pro BNP levels and left ventricular wall stress, sphericity index and extent of myocardial damage: a magnetic resonance imaging study. , 2008, Journal of cardiac failure.

[9]  A. Remppis,et al.  Improved guideline adherence to pharmacotherapy of chronic systolic heart failure in general practice--results from a cluster-randomized controlled trial of implementation of a clinical practice guideline. , 2008, Journal of evaluation in clinical practice.

[10]  Gianni Tognoni,et al.  Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). , 2008, Journal of the American College of Cardiology.

[11]  S. Réhman,et al.  Natriuretic Peptide Testing in Clinical Medicine , 2008, Cardiology in review.

[12]  W Frank Peacock,et al.  State of the art: Using natriuretic peptide levels in clinical practice , 2008, European journal of heart failure.

[13]  G. Fonarow,et al.  Cardiac troponin and outcome in acute heart failure. , 2008, The New England journal of medicine.

[14]  R. Fitzgerald,et al.  Pro-B-type natriuretic peptide levels in acute decompensated heart failure. , 2008, Journal of the American College of Cardiology.

[15]  Juan Cinca,et al.  Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. , 2008, European heart journal.

[16]  L. Newby,et al.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. , 2008, Clinical biochemistry.

[17]  W. Remme,et al.  Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure , 2008, Cardiovascular Drugs and Therapy.

[18]  J. Januzzi,et al.  Biology of the natriuretic peptides. , 2008, The American journal of cardiology.

[19]  A. Maisel,et al.  State-of-the-Art PaperNatriuretic Peptides , 2007 .

[20]  M. Komajda,et al.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey , 2007, European journal of heart failure.

[21]  A. Bayés‐Genís,et al.  Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. , 2007, International journal of cardiology.

[22]  P. Poole‐Wilson,et al.  Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial , 2007, European journal of heart failure.

[23]  C. Specchia,et al.  The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT‐proBNP and cardiac troponin‐T , 2007, European journal of heart failure.

[24]  Robert H Christenson,et al.  National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. , 2007, Circulation.

[25]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[26]  J. Burnett,et al.  Natriuretic peptides and therapeutic applications , 2007, Heart Failure Reviews.

[27]  J. Cleland,et al.  Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[28]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[29]  K. Swedberg,et al.  International variations in the treatment and co‐morbidity of left ventricular systolic dysfunction: Data from the EuroHeart Failure Survey , 2007, European journal of heart failure.

[30]  D. Phelan,et al.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. , 2007, Journal of cardiac failure.

[31]  C. Mueller,et al.  The integration of BNP and NT-proBNP into clinical medicine. , 2007, Swiss medical weekly.

[32]  P. Hildebrandt,et al.  Unexplained week‐to‐week variation in BNP and NT‐proBNP is low in chronic heart failure patients during steady state , 2007, European journal of heart failure.

[33]  Alan H B Wu,et al.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.

[34]  A. Ferreira,et al.  Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. , 2006, The American journal of cardiology.

[35]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[36]  R. Vasan,et al.  Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations , 2006, Circulation.

[37]  M. Pfisterer,et al.  Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.

[38]  C. Frampton,et al.  Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.

[39]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.

[40]  J. H. Patterson,et al.  Executive Summary Executive Summary : HFSA 2010 Comprehensive Heart Failure Practice Guideline , 2022 .

[41]  K. Swedberg,et al.  Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure. , 2005, European heart journal.

[42]  A. Jaffe,et al.  Troponin: the biomarker of choice for the detection of cardiac injury , 2005, Canadian Medical Association Journal.

[43]  R. Califf,et al.  Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.

[44]  W. Burdick.  The N-Terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study , 2005 .

[45]  John G.F. Cleland,et al.  Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. , 2005, Journal of the American College of Cardiology.

[46]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[47]  A. Ferreira,et al.  N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.

[48]  S. Ogawa,et al.  Brain natriuretic peptide response is heterogeneous during β-blocker therapy for congestive heart failure , 2004 .

[49]  Hugo A Katus,et al.  NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy , 2004, European journal of heart failure.

[50]  Gabriel Thabut,et al.  Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.

[51]  Peter C Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[52]  J. Sanderson,et al.  Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. , 2003, The American journal of cardiology.

[53]  A. Kerr,et al.  Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. , 2003, Journal of the American College of Cardiology.

[54]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[55]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. , 2002, Journal of the American College of Cardiology.

[56]  L. Morrison,et al.  Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea ☆ , 2002 .

[57]  K. Adams.  Which ?-blocker for heart failure? , 2001 .

[58]  T. Ohtsuka,et al.  Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. , 2000, Japanese circulation journal.

[59]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[60]  D. Kass.  Rescuing a failing heart: putting on the squeeze , 2009, Nature Medicine.

[61]  Karen A. Hartman,et al.  Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. , 2009, Clinical chemistry.

[62]  Mark E. Anderson,et al.  Rescuing a failing heart: think globally, treat locally , 2009, Nature Medicine.

[63]  G. Kimura,et al.  Within-person variation of the plasma concentration of B-type natriuretic peptide: safety range in stable patients with heart failure. , 2009, American heart journal.

[64]  G. Novo,et al.  Biomarkers in heart failure. , 2009, Frontiers in bioscience.

[65]  J. Cohn,et al.  Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.

[66]  K. Adams.  Which beta-blocker for heart failure? , 2001, American Heart Journal.